FdaApplication
NDA 212614
Identifiers
- fda_app_no: NDA212614
Properties
| Property | Value |
|---|---|
| applicant_name | BOEHRINGER INGELHEIM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2020-01-27 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 25MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL |
| TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL |
| TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 12.5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL |
| TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 10MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL |
4 products